A news of 2003, in addition to the World which is not a reference in medicine, is to look for the little beast
Rather in those who know and do not tell salads
Indeed it is not a reference, neither in medicine, nor elsewhere either, and I will remind you when you refer to it. However, they did not find that under the hoof of a horse!
Between 1991 and 2015, the cancer mortality rate has decreased by 26%. Results linked to earlier detection of cancers, better treatments ... and stopping smoking
https://www.pourquoidocteur.fr/Articles ... the world
I do not know if this site is better than the world where everyone draws happiness from luck according to what he wants to put forward, it is also and why I prefer official sites like INVS, or INSERM, rather than others (although their conclusions are also oriented)
Examples:
http://www.ipubli.inserm.fr/bitstream/h ... uence=1629Breast cancer
ANALYSIS
Incidence and evolution
Breast cancer is the most common cancer in women worldwide, in Western European and North American countries (Parkin et al., 2002), and in Japan recently (Minami et al ., 2004). In France, the standardized breast cancer incidence rate on the world age structure is the highest in Europe. This number doubled in 20 years, starting from 21 000 new cases in 1980 (Remontet et al., 2003a and b). Comparatively, breast cancer in humans is extremely rare.
Impact in the world
The incidence of breast cancer is steadily increasing. The number of new breast cancers diagnosed with 2000 was estimated at more than one million, accounting for 22% of women's cancers (Parkin et al., 2001, Althuis et al., 2005). The incidence of this cancer varies greatly by region of the world with a ratio of 1 to 5 between high-impact industrialized countries and low-incidence developing countries. The International Agency for Research on Cancer has observed cancer incidence data for the 1993-1997 period (Parkin et al., 2002). The highest incidence rates are observed in the United States with 100 cases for 100 000 women, and Western and Northern Europe. Rates are intermediate in Eastern Europe, some southern European countries such as Spain and South America. The lowest rates are in Africa and Asia (they can even be lower than 20 for 100 000) including Japan, which is an industrialized country.
Incidence rates, between 60 and 80 / 100 000 among Asian, Hispanic and Black populations in the United States, are intermediate between the incidence observed in the white women population, which often have rates greater than 100 / 100 000, and the low incidence observed in Asia or Africa.
Incidence in France
In France, the French Network of Cancer Registries (Francim) estimates 49 814 the number of new cases diagnosed in 2005 (http://www.invs.sante.fr/). As at the global and European level, breast cancer is the 1 rank of all women's cancers. The standardized incidence rate of 101,5 for 100 000 Women is among the highest in Europe. It represents 36% of all new cases of cancer in women in France. The incidence increases very rapidly before 50 years until reaching a peak in women 60-69 years (Figure 27.1).
Figure 27.1 Estimated incidence of breast cancer by age (France, according to Francim, InVS, Hospices civils de Lyon)
The shape of the age-specific breast cancer incidence curve differs across populations and over time. In most Western populations, the incidence increases sharply with age until the onset of menopause, which is then followed by a steeper slope increase (Henderson et al., 1996). The incidence curve in France for the same birth cohort (1928) is consistent with this description. Transversally, that is, for all birth cohorts observed at a given date (2000), a peak of incidence is observed between 60 and 69 years, followed by a decrease in the incidence rate. This decrease results from a lower risk of breast cancer in the oldest birth cohorts.
These incidence figures do not include in situ cancers, which can represent between 5 and 15% of all breast cancers according to the départements in France.
The ductal carcinoma accounts for the vast majority (85%) of the histological forms of breast cancer.
Evolution of incidence
Incidence has increased steadily in most parts of the world (Bray et al., 2004). The evolution of age-related incidence is complex to describe.
In the world
The increase, on average from 20 to 40% between 1973-1977 and 1993-1997, was more pronounced especially in countries with a lower initial incidence rate as in Japan, Finland or in developing countries (Althuis et al., 2005). In Europe, all countries showed an increase in incidence, the average rates of variation ranged from 1,2% per year in Switzerland to 3% in the Czech Republic in the 1985-1997 period (Botha et al., 2003). Rates of change were higher in the age group of women screened. A recent striking feature is the trend reversal in the United States, where a decrease in incidence has been observed since the early 2000 years among women over the age of 45-50 (Jemal et al., 2007, Ravdin and coll., 2007; Ries et al., 2007).
The evolution of the incidence as a function of age depends simultaneously on the effect of the birth cohort, linked to changes in the lifestyle of women, and the effect of the period, linked in particular to changes in the mode of life. of cancer discovery. A cohort effect is systematically highlighted, but at different times in different countries (Estève, 2007). After a significant increase, a decrease in the risk of developing breast cancer has occurred in some countries (United States, Canada, Scotland) for women born after 1945 (Tarone, 2006). Period effects occur in different forms: trend disruptions have been observed, particularly in the United States with a significant increase in incidence in women over 45 years between 1980 and 2000 in relation to rapid changes in practices. . On the contrary, other countries, such as France, had a more regular period effect, probably linked to the progressive development of individual and organized screening practices.
It is therefore difficult to distinguish the combined effects of the multiple factors that may be involved in the evolution of breast cancer incidence. Schematically, the increase observed in recent decades is largely attributed to the development of screening in industrialized countries. However, the part linked to the increase in risk factors is still poorly understood.
In France
The incidence of breast cancer has been steadily increasing since 25 years: the number of new cases has more than doubled from 21 704 to 49 814 between 1989 and 2005 and the standardized incidence rate, eliminating the effect of age, almost doubled over this period from 56,8 to 101,5 for 100 000 women (Figure 27.2). The average annual rate of change of 2,4% over the entire period is slightly lower (+ 2,1% per year) over the last period (2000-2005). An additional work by Francim (Colonna et al., 2008) showed that the increase affects all age groups but is more pronounced in women from 50 to 75 years. This age group represents women in whom the peak incidence of breast cancer is observed but also women for whom systematic mammographic screening is recommended.
Figure 27.2 Evolution of the estimated incidence of breast cancer from 1980 to 2005 in France (according to Francim, InVS, Hospices civils de Lyon)
The risk of developing breast cancer before 75 years has increased dramatically from 4,9% for women born in 1910 to 12,1% for women born in 1950 (Figure 27.3). However, after a particularly marked increase in this risk for women born between 1925 and 1945, there is a shift in the increase for the generation of women born after 1945. This slowdown in women of the most recent generations may signal a decline in the increase in incidence, as also suggested by the lower rate of change between 2000 and 2005.
Figure 27.3 Cumulative risk 0-74 years of breast cancer according to the birth cohort (according to Francim, InVS, Hospices civils de Lyon)
Survival
In the world
In a recent study (Eurocare 4), conducted by European cancer registries, the relative survival rate for 5 years is estimated at 81% on average in Europe after a breast cancer diagnosis over the 1995-1999 period (Berrino et al. coll., 2007). Despite a faster increase in survival in the Eastern and Southern countries between 1990-1994 and 1995-1999, a gap persists with better survival observed in Northern and Central European countries. The relative survival rate estimated at 90,1% at 5 years in 2000-2002 remains higher in the United States than in Europe (Verdecchia et al., 2007).
In France
The French cancer registries, in partnership with the Hospices Civils de Lyon, conducted a survival study on all cancers recorded in their databases from 1989 to 1997 (Bossard et al., 2007). The standardized relative survival rate at 5 years increased from 82% in 1989-1991 to 86% in 1995-1997, thus placing France among the countries with the best survival after breast cancer (Sauvage et al., 2007).
In conclusion, breast cancer is at the 1er rank of women's cancers. The incidence has steadily increased over the last 25 years, but there is currently a shift in the increase for the generation of women born after 1945, which could signal a shift in the incidence increase. The increase observed in recent decades is partly due to the development of screening in industrialized countries, but the part linked to the increase in risk factors is still poorly known.
All agree (IARC, WHO ...) but you will get the info from behind the fagots that kills his race.
Have you become Arab?
The disadvantage of a vision, globalizing, gives an information often distorted also (especially coming from the WHO now to 80% at the hands of the labs.) Examines the curve 27-1 which according to the ages goes from a minimum to a maximum and where an average does not mean anything, for example.
Cancer mortality has decreased by 1,5% per year in men and 1% per year in women between 1980 and 2012 (standardized rates).
This decline is related to earlier diagnoses, more effective treatments, and overall lower risk of dying from cancer.
http://www.e-cancer.fr/Comprendre-preve ... ffres-cles
however:
This study shows that cancer detection efforts have paid off in the United States. "We note, in particular, the impact of the fight against smoking," says Otis W. Brawley, Chief Medical Officer of the American Cancer Society. "THE DECLINE IN CIGARETTE CONSUMPTION IS ONE OF THE MOST IMPORTANT FACTORS FOR THE DECLINE IN THE MORTALITY RATE OF CANCER".Indeed, the curves show that it is mainly the decrease and cessation of smoking in men that has seriously influenced the mortality curve offset by the increase in women for the same causes. Moreover, citizens' awareness of chemicals in agriculture, food (dyes, preservatives, taste adjuvants, etc.) in medicine, cleaning products, hygiene (rejection of aluminum in cosmetics, but not in vaccines), etc ... have also had a significant impact in reducing carcinogenic factors.
"We make science with facts, like making a house with stones: but an accumulation of facts is no more a science than a pile of stones is a house" Henri Poincaré